|
|
|
|
|
18.04.26 - 05:00
|
As China′s biotech firms shift gears, can AI floor the accelerator? (SCMP)
|
|
|
A quarter featuring multiple eye-popping deals is no longer unusual for China's pharmaceutical industry – in fact, it may soon be considered a slow season.
In recent months, companies including CSPC Pharmaceutical and RemeGen have struck out-licensing agreements worth up to US$18.5 billion and US$5.6 billion respectively, while Haisco Pharmaceutical Group has added two of its own — most recently a deal worth up to US$745 million.
Under the terms of the deal, the Beijing-based Haisco granted US......
|
|
|
|
|
|
|
|
|
|
|
|
|
17.04.26 - 13:31
|
Abspaltung der Siemens-Medizintechnik erst im Jahr 2027 (Dow Jones)
|
|
|
DOW JONES--Die Abspaltung der Siemens-Medizintechnik vom Mutterkonzern wird erst im nächsten Jahr stattfinden. Die Siemens-Aktionäre sollen darüber auf der ordentlichen Siemens-Hauptversammlung im Februar 2027 abstimmen, wie der Technologiekonzern mitteilte. ......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.04.26 - 06:00
|
How Hong Kong′s role as innovation hub helps healthcare and biotech firms (SCMP)
|
|
|
Many world-class cities are prioritising efforts to enhance their health technology infrastructures to attract more clinical trials and research projects. These can offer many benefits not only to pharmaceutical companies and research institutes, but also – potentially – give the public better access to innovative treatment options and raise the overall quality of their healthcare system.
Hong Kong, backed by two top‑ranked medical schools and one of the world's most active capital markets, is......
|
|